Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) FCF Margin (2016 - 2017)

Historic FCF Margin for Soleno Therapeutics (SLNO) over the last 4 years, with Q2 2017 value amounting to 299100.0%.

  • Soleno Therapeutics' FCF Margin fell 971000000.0% to 299100.0% in Q2 2017 from the same period last year, while for Mar 2018 it was 1085600.0%, marking a year-over-year decrease of 10842705000.0%. This contributed to the annual value of 30007.79% for FY2024, which is N/A changed from last year.
  • Per Soleno Therapeutics' latest filing, its FCF Margin stood at 299100.0% for Q2 2017, which was down 971000000.0% from 825.28% recorded in Q1 2017.
  • Soleno Therapeutics' 5-year FCF Margin high stood at 172.69% for Q2 2014, and its period low was 299100.0% during Q2 2017.
  • For the 4-year period, Soleno Therapeutics' FCF Margin averaged around 36962.91%, with its median value being 920.26% (2016).
  • Data for Soleno Therapeutics' FCF Margin shows a peak YoY increase of 73317500bps (in 2016) and a maximum YoY decrease of -1992164900bps (in 2016) over the last 5 years.
  • Quarter analysis of 4 years shows Soleno Therapeutics' FCF Margin stood at 67.07% in 2014, then crashed by -2035bps to 1297.92% in 2015, then grew by 27bps to 944.99% in 2016, then tumbled by -31551bps to 299100.0% in 2017.
  • Its FCF Margin was 299100.0% in Q2 2017, compared to 825.28% in Q1 2017 and 944.99% in Q4 2016.